|5,7-二甲基-N-(反式-4-(戊氧基)环己基)吡唑并[1,5-a]嘧啶-3-甲酰胺|CsnPharm

CAS No.: 1919820-28-2

Gcase activator 1 Catalog No. CSN21251

Synonyms: LTI-291

LTI-291, a extract from patent WO 2017192841 A1, is an activator of glucocerebrosidase (Gcase) for treatment of Parkinson's disease.

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

描述Mutations in GBA1, the gene encoding the lysosomal enzyme glucocerebrosidase, may lead to degradation of the protein, disruptions in lysosomal targeting and diminished performance of the enzyme in the lysosome, and are among the most common known genetic risk factors for the development of Parkinson disease and related synucleinopathies. Mutations in the gene encoding glucocerebrosidase (Gcase) are a risk factor for Parkinson's disease and diffuse Lewy Body Disease^[1]. LTI-291 is an activator of the GCase enzyme used for the treatment of Parkinson's disease. In a one-month phase 1b trial, there were no safety events and data showed a good dose-dependent brain penetration after 10 or 60 mg once daily oral treatment^[2].
参考文献

[1] Methods of treatment and combination therapies using gcase activator heterobicyclic and related compounds
[2] Schneider SA, Alcalay RN. Precision medicine in Parkinson's disease: emerging treatments for genetic Parkinson's disease. J Neurol. 2020 Mar;267(3):860-869

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 2.7896 mL
- 13.9479 mL
- 27.8957 mL
- 5 mM
- 0.5579 mL
- 2.7896 mL
- 5.5791 mL
- 10 mM
- 0.2790 mL
- 1.3948 mL
- 2.7896 mL

技术信息

CAS号

1919820-28-2

储存条件

粉末: Inert atmosphere,Room Temperature

液体: -20°C:3-6 月 -80°C:12月

分子式

C20H30N4O2

运输

蓝冰

分子量

358.48

别名

LTI-291

溶解度

DMSO	60.0 mg/mL (167.4 mM) warming
Water	insoluble

动物实验配方

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

Gcase activator 1 Catalog No. CSN21251

靶点选择性

请登录您的专属账户

确认信息